Ann D. B.
- Country
- Belgium
- Department
- Hematology
Research Overview
- A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications
- Evaluation of Blinatumomab, Isatuximab, and Ponatinib in Frontline Therapy for Adults with Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 205 of 404 partner sites.
Specializations
Leukemia Treatment
The investigator specializes in treating various forms of acute leukemia, with particular focus on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Their research encompasses innovative therapies including Menin-MLL inhibitors and venetoclax-based treatments.
- Relapsed/Refractory AML Management
- Novel Therapeutic Approaches for ALL
- Combination Therapy Strategies
Multiple Myeloma Innovations
Their expertise extends to multiple myeloma treatment, particularly focusing on patients with suboptimal responses to conventional therapies. The investigator works with advanced treatments including CAR T-cell therapy and novel therapeutic combinations.
- Post-Transplant Treatment Strategies
- Immunotherapy Applications
- Maintenance Therapy Optimization
Transplant and Cellular Therapy
The investigator has significant experience in hematopoietic stem cell transplantation and its complications, including graft-versus-host disease (GvHD). Their work includes evaluating microbiome-based therapies and monitoring long-term outcomes of gene-modified T cell treatments.
- GvHD Management
- Transplant Complications
- Cell Therapy Safety Monitoring
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.